Vaccines for the 21st Century - A Tool for Decisionmaking (Hardcover, New)

Vaccines have made it possible to eradicate the scourge of smallpox, promise the same for polio, and have profoundly reduced the threat posed by other diseases such as whooping cough, measles, and meningitis. What is next? There are many pathogens, autoimmune diseases, and cancers that may be promising targets for vaccine research and development. This volume provides an analytic framework and quantitative model for evaluating disease conditions that can be applied by those setting priorities for vaccine development over the coming decades. The committee describes an approach for comparing potential new vaccines based on their impact on morbidity and mortality and on the costs of both health care and vaccine development. The book examines: Lessons to be learned from the polio experience. Scientific advances that set the stage for new vaccines. Factors that affect how vaccines are used in the population. Value judgments and ethical questions raised by comparison of health needs and benefits. The committee provides a way to compare different forms of illness and set vaccine priorities without assigning a monetary value to lives. Their recommendations will be important to anyone involved in science policy and public health planning: policymakers, regulators, health care providers, vaccine manufacturers, and researchers. Table of Contents Front Matter Executive Summary Introduction Progress in Vaccine Development Considerations of Candidate Vaccines Overview of Analytic Approach and Results Review of the Analytical Model Ethical Considerations and Caveats Observations References Appendix 1: Borrelia burgdorferi Appendix 2: Chlamydia Appendix 3: Coccidioides Immitis Appendix 4: Cytomegalovirus Appendix 5: Enterotoxigenic E. coli Appendix 6: Epstein-Barr Virus Appendix 7: Helicobacter pylori Appendix 8: Hepatitis C Appendix 9: Herpes Simplex Virus Appendix 10: Histoplasma capsulatum Appendix 11: Human Paillomavirus Appendix 12: Influenza A and B Appendix 13: Insulin-Dependent Diabetes Mellitus Appendix 14: Melanoma Appendix 15: Multiple Sclerosis Appendix 16: Mycobacterium tuberculosis Appendix 17: Neisseria gonnorrhea Appendix 18: Neisseria meningitidis Appendix 19: Parainfluenza Virus Appendix 20: Respiratory Syncytial Virus Appendix 21: Rheumatoid Arthritis Appendix 22: Rotavirus Appendix 23: Shigella Appendix 24: Streptococcus, Group A Appendix 25: Streptococcus, Group B Appendix 26: Streptococcus pneumoniae Appendix 27: Information on accessing Electronic Spreadsheets Appendix 28: Summary of Workshops Appendix 29: Questions Posed to Outside Experts and List of Responders Index

General

Imprint:	National Academies Press
Country of origin:	United States
Release date:	March 2001
First published:	February 2001
Authors:	Institute of Medicine • Division of Health Promotion and Disease Prevention • Committee to Study Priorities for Vaccine Development
Editors:	Robert S. Lawrence • Jane S. Durch • Kathleen R. Stratton
Dimensions:	229 x 152 x 35mm (L x W x T)
Format:	Hardcover
Pages:	472
Edition:	New
ISBN-13:	978-0-309-05646-5
Categories:	Books > Medicine > General issues > Health systems & services > General Books > Medicine > Other branches of medicine > Pharmacology > General
LSN:	0-309-05646-2
Barcode:	9780309056465

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!